Filters

Documents

Showing 25 of 860 items meeting your criteria.
Items per page
 TypeCategorySupplier 
 
Xeno-free, serum-free media for human T cell cultivation
Documents
Cell Culture
Xcell Therapeutics Inc.
Rapid & reliable detection of Niaph Virus via lateral flow.
Documents
Virology
LeadGene Biomedical
Founded in 2018 as an academic spin-off based on unique DIANA technology for drug discovery and diagnostics, bringing deep expertise in molecular biology, chemistry and informatics. All operations are based in the heart of Europe: Prague, Czech Republic. With our expertise in protein engineering, we develop and produce unique and high-performance reagents for PCR, RT-PCR, RNA production, NGS and sample preparation in research, development and diagnostics.
Documents
Catalogue
DIANA Biotechnologies
DBdirect PCR & qPCR mixes SuperSens 2.0 | DB SuperSens Taq DNA Polymerase | DB AptaTaq DNA Polymerase
Documents
Molecular Biology
DIANA Biotechnologies
DB RNase Inhibitors | DBscript Reverse Transcriptase | Products for cDNA synthesis | One-Step DB RT-PCR & RT-qPCR mixes SuperSens 2.0 | One-Step DBdirect RT-qPCR mixes SuperSens 2.0
Documents
Molecular Biology
DIANA Biotechnologies
The most stable and potent inhibitor on the market.
Documents
Molecular Biology
DIANA Biotechnologies
At DIANA Biotechnologies, we deliver top-quality custom DNA and RNA oligonucleotides tailored to your needs. With a wide range of modifications, we guarantee the highest purity, quality, and yield at competitive prices.
Documents
Service
DIANA Biotechnologies
Fluorescent Dyes for High-Performance Labeling
Documents
Dyes and Stains
DIANA Biotechnologies
Antibodies derived from alpacas or llamas with great penetrability and affinity to recognize novel epitopes.
Documents
Antibodies
Abnova Corporation
Cloud-Clone provides high-quality raw materials to support global new drug development, biopharmaceutical companies, diagnostic reagent manufacturers, and CROs.
Documents
Proteins
Cloud-Clone Corp.
Elabscience Uncoated ELISA Kits offer a versatile and cost-effective option that enables stable workflows while delivering high-quality results.
Documents
ELISA
Elabscience
Tired of matrix effects in complex cell samples? The CellaQuant ELISA Kit overcomes traditional limitations to deliver high sensitive, specific and reliable results in challenging cellular matrices.
Documents
ELISA
Elabscience
Optimized Efficiency, Low Toxicity
Documents
Transfection
Elabscience
The optimal choice for pure and efficient exosome isolation
Documents
Cell Culture
Elabscience
Cutting-Edge, Ready-to-Use Formulations for Seamless Cell Expansion
Documents
Cell Culture
Elabscience
Classical to specialised - media that grow with your cell-based projects
Documents
Cell Culture
Elabscience
Precision requires the right tools. Whether you are building complex neurovascular units or scaling xeno-free translational models, there is an OptiCulture™ serum-free system designed for your specific microenvironment.
Documents
Cell Culture
Cell Systems
Efficient Cell Isolation, Simple and Fast Workflow, High Compatibility, Reliable Quality
Documents
Cell Based Assays
Elabscience
Empowering your neuroscience research. Accelerating drug discovery, development and translation for nervous system disorders.
Documents
Neuroscience
iXCells Biotechnologies
T Cell Immunoreceptor with Immunoglobulin and ITIM domains (TIGIT, VSTM3) is an immune checkpoint receptor expressed on the surface of cytotoxic, memory and regulatory T cells (Tregs) as well as natural killer (NK) cells. TIGIT binding to CD155 (PVR) and CD112 (Nectin-2) suppresses immune activation on cytotoxic T cells and NK cells. In the normal immune system, the suppressive effect of TIGIT is counterbalanced by the immune-activating receptor CD226 (DNAM1), which competes with TIGIT to bind CD155 and CD112. The inhibitory signal provided by TIGIT overpowers the ability of CD226 to stimulate T cell activation. Tumor cells exploit the dominance of the inhibitory TIGIT pathway to avoid immune-mediated destruction. Overexpression of TIGIT and reduced CD226 activity are frequently observed in exhausted T cells within tumors, making the TIGIT/CD226 axis a key focus for immune checkpoint blockade strategies.
Documents
Immunology
AdipoGen Life Sciences
PD-1 (Programmed Cell Death Protein 1; CD279) is a type I transmembrane protein belonging to the CD28/CTLA-4 family of immune receptors. PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC; CD273) are immuno-coinhibitory ligands of the B7 family binding to PD-1. The PD-1/PD-L1 or PD-L2 signaling pathway is a negative regulatory mechanism that inhibits T cell proliferation and cytokine production. Blockade of the PD-1/PD-L1 interaction enhances antitumor immunity. The PD-1 pathway plays a major role in the inhibition of self-reactive T cells and protection against autoimmune diseases. PD-1 and PD-L1 also exist as soluble forms. Elevated levels of soluble PD-1 (sPD-1) are shown in rheumatoid arthritis, skin sclerosis and autoimmune hepatitis. Levels of sPD-L1 are increased in the plasma of cancer patients as well as in cerebrospinal fluid of gliomas. sPD-L1 is a biomarker of poor survival in patients with B cell lymphoma, renal cell carcinoma, metastatic melanoma or lung cancer and is associated with advanced tumor stages.
Documents
Immunology
AdipoGen Life Sciences
Beyond the well-characterized B7-1 (CD80), B7-2 (CD86) and PD-L1/PD-L2 pathways, newer B7 family ligands, B7-H3, B7- H4, B7-H5 (VISTA) and B7-H6, have emerged as important regulators of immune responses with significant interest in immunotherapy research. They are all overexpressed in tumors correlating with immune escape and resistance to antitumor responses.
Documents
Immunology
AdipoGen Life Sciences
The herpesvirus entry mediator (HVEM; CD270; TNFRSF14) represents a central hub in immune regulation, orchestrating complex interactions with multiple partners, including BTLA, LIGHT and CD160. HVEM is a molecular switch that acts both as an immune system stimulator and as an inhibitor. It is expressed in T cells, B cells, natural killer cells, dendritic cells and endothelial cells. LIGHT is an immune stimulator that contributes to dendritic cell maturation and T cell expansion. The immune suppressor BTLA functions in opposition to LIGHT by inhibiting naïve T cell expansion and induction of Treg cells. CD160 acts as an immune suppressor through its interactions with HVEM. The checkpoint receptors/ligands system HVEM, LIGHT, CD160 and BTLA (CD272) is part of a complex network of overlapping receptor interactions that function in both immune stimulation and suppression and which is a potential therapeutic target for treatment of autoimmune diseases and allergies and controlling antitumor responses.
Documents
Immunology
AdipoGen Life Sciences
OX40 (CD134; TNFRSF4) is an activating receptor, a member of the TNF receptor superfamily, expressed on the surface of activated cytotoxic T cells and regulatory T cells (Tregs). OX40 both activates and amplifies T cell responses. On cytotoxic T cells, OX40 binds to its ligand OX40L (CD252; TNFSF4), resulting in stimulatory signals that promote T cell reproduction, function and survival. OX40/OX40L signaling blocks the ability of Tregs to suppress T cells and reduces Treg generation. By inhibiting the immunosuppressive effect of Tregs and limiting their population, OX40 further amplifies the impact of T cell activation. The dual effects of OX40 help to create a tumor microenvironment that is more favorable to the antitumor immune response. The OX40-OX40L axis is a versatile and promising target across oncology, autoimmunity, and chronic inflammatory disease research.
Documents
Immunology
AdipoGen Life Sciences
Inducible T Cell Co-Stimulator (ICOS; CD278) is an activating receptor expressed on the surface of activated cytotoxic T cells, regulatory T cells (Tregs), natural killer (NK) cells and other types of T cells, having a distinct and opposing function than CTLA-4. The ligand ICOSL (B7-H2; CD275) is expressed on antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages. ICOS/ICOSL signaling leads to the activation, proliferation and survival of cytotoxic T cells, as well as the survival of memory T cells. ICOS/ICOSL binding generates various activities including T cell activation and effector functions and when sustained also suppressive activities mediated by regulatory T cells. This dual role in both anti-tumor and pro-tumor activities makes targeting the ICOS/ICOSL pathway attractive for enhancement of anti-tumor immune responses and as a potential biomarker for disease treatment and prognostic prediction.
Documents
Immunology
AdipoGen Life Sciences